Eli Lilly aid on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for US patients, as demand for weight-loss therapies surge.Patients with…
Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new chief executive. Revenue will rise only as much…
Novo Nordisk has launched a surprise $9bn (£6.9bn) offer for the US obesity-focused biotech firm Metsera that could gazump an existing bid from Pfizer as the pharmaceutical giants fight for dominance in the weight-loss market.The…